vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and IDEX Corporation (IEX). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $398.4M, roughly 1.2× IDEX Corporation). IDEX Corporation runs the higher net margin — 30.1% vs -10.1%, a 40.2% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 16.7%). IDEX Corporation produced more free cash flow last quarter ($86.0M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -29.4%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.

CLOV vs IEX — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.2× larger
CLOV
$487.7M
$398.4M
IEX
Growing faster (revenue YoY)
CLOV
CLOV
+28.1% gap
CLOV
44.7%
16.7%
IEX
Higher net margin
IEX
IEX
40.2% more per $
IEX
30.1%
-10.1%
CLOV
More free cash flow
IEX
IEX
$155.0M more FCF
IEX
$86.0M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-29.4%
IEX

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
CLOV
CLOV
IEX
IEX
Revenue
$487.7M
$398.4M
Net Profit
$-49.3M
$120.0M
Gross Margin
99.9%
Operating Margin
-10.1%
43.3%
Net Margin
-10.1%
30.1%
Revenue YoY
44.7%
16.7%
Net Profit YoY
-123.2%
25.7%
EPS (diluted)
$1.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
IEX
IEX
Q2 26
$398.4M
Q1 26
$407.7M
Q4 25
$487.7M
$899.1M
Q3 25
$496.6M
$878.7M
Q2 25
$477.6M
$865.4M
Q1 25
$462.3M
$814.3M
Q4 24
$337.0M
$862.9M
Q3 24
$331.0M
$798.2M
Net Profit
CLOV
CLOV
IEX
IEX
Q2 26
$120.0M
Q1 26
$128.3M
Q4 25
$-49.3M
$128.3M
Q3 25
$-24.4M
$127.8M
Q2 25
$-10.6M
$131.6M
Q1 25
$-1.3M
$95.5M
Q4 24
$-22.1M
$123.2M
Q3 24
$-9.2M
$119.1M
Gross Margin
CLOV
CLOV
IEX
IEX
Q2 26
99.9%
Q1 26
94.9%
Q4 25
43.1%
Q3 25
44.5%
Q2 25
45.3%
Q1 25
45.3%
Q4 24
42.5%
Q3 24
24.5%
44.3%
Operating Margin
CLOV
CLOV
IEX
IEX
Q2 26
43.3%
Q1 26
45.0%
Q4 25
-10.1%
20.4%
Q3 25
-4.9%
21.1%
Q2 25
-2.2%
21.7%
Q1 25
-0.3%
17.4%
Q4 24
-6.4%
19.2%
Q3 24
-2.7%
21.0%
Net Margin
CLOV
CLOV
IEX
IEX
Q2 26
30.1%
Q1 26
31.5%
Q4 25
-10.1%
14.3%
Q3 25
-4.9%
14.5%
Q2 25
-2.2%
15.2%
Q1 25
-0.3%
11.7%
Q4 24
-6.6%
14.3%
Q3 24
-2.8%
14.9%
EPS (diluted)
CLOV
CLOV
IEX
IEX
Q2 26
$1.61
Q1 26
$1.71
Q4 25
$1.71
Q3 25
$1.70
Q2 25
$1.74
Q1 25
$1.26
Q4 24
$1.61
Q3 24
$1.57

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
IEX
IEX
Cash + ST InvestmentsLiquidity on hand
$78.3M
$586.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$4.0B
Total Assets
$541.0M
$6.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
IEX
IEX
Q2 26
$586.2M
Q1 26
$580.0M
Q4 25
$78.3M
$580.0M
Q3 25
$593.8M
Q2 25
$568.2M
Q1 25
$594.1M
Q4 24
$194.5M
$620.8M
Q3 24
$288.0M
$633.2M
Total Debt
CLOV
CLOV
IEX
IEX
Q2 26
Q1 26
Q4 25
$1.8B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$2.0B
Q4 24
$2.0B
Q3 24
$2.1B
Stockholders' Equity
CLOV
CLOV
IEX
IEX
Q2 26
$4.0B
Q1 26
$4.0B
Q4 25
$308.7M
$4.0B
Q3 25
$340.9M
$4.0B
Q2 25
$344.2M
$4.0B
Q1 25
$336.1M
$3.9B
Q4 24
$341.1M
$3.8B
Q3 24
$342.2M
$3.8B
Total Assets
CLOV
CLOV
IEX
IEX
Q2 26
$6.9B
Q1 26
$6.9B
Q4 25
$541.0M
$6.9B
Q3 25
$559.7M
$7.0B
Q2 25
$575.0M
$6.9B
Q1 25
$583.7M
$6.8B
Q4 24
$580.7M
$6.7B
Q3 24
$653.0M
$7.0B
Debt / Equity
CLOV
CLOV
IEX
IEX
Q2 26
Q1 26
Q4 25
0.45×
Q3 25
0.48×
Q2 25
0.46×
Q1 25
0.50×
Q4 24
0.52×
Q3 24
0.55×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
IEX
IEX
Operating Cash FlowLast quarter
$-66.9M
Free Cash FlowOCF − Capex
$-69.0M
$86.0M
FCF MarginFCF / Revenue
-14.1%
21.6%
Capex IntensityCapex / Revenue
0.4%
4.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$654.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
IEX
IEX
Q2 26
Q1 26
Q4 25
$-66.9M
$209.5M
Q3 25
$12.1M
$203.5M
Q2 25
$5.4M
$161.7M
Q1 25
$-16.3M
$105.7M
Q4 24
$34.8M
$172.6M
Q3 24
$50.0M
$205.3M
Free Cash Flow
CLOV
CLOV
IEX
IEX
Q2 26
$86.0M
Q1 26
$189.8M
Q4 25
$-69.0M
$189.8M
Q3 25
$11.4M
$188.7M
Q2 25
$4.8M
$146.9M
Q1 25
$-16.5M
$91.4M
Q4 24
$33.3M
$157.1M
Q3 24
$49.6M
$191.6M
FCF Margin
CLOV
CLOV
IEX
IEX
Q2 26
21.6%
Q1 26
46.6%
Q4 25
-14.1%
21.1%
Q3 25
2.3%
21.5%
Q2 25
1.0%
17.0%
Q1 25
-3.6%
11.2%
Q4 24
9.9%
18.2%
Q3 24
15.0%
24.0%
Capex Intensity
CLOV
CLOV
IEX
IEX
Q2 26
4.4%
Q1 26
15.6%
Q4 25
0.4%
2.2%
Q3 25
0.1%
1.7%
Q2 25
0.1%
1.7%
Q1 25
0.0%
1.8%
Q4 24
0.5%
1.8%
Q3 24
0.1%
1.7%
Cash Conversion
CLOV
CLOV
IEX
IEX
Q2 26
Q1 26
Q4 25
1.63×
Q3 25
1.59×
Q2 25
1.23×
Q1 25
1.11×
Q4 24
1.40×
Q3 24
1.72×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons